Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease.
Růzicka
E
E
Department of Neurology, Movement Disorders Center, Charles University, Prague, Czech Republic.
Roth
J
J
Jech
R
R
Busek
P
P
D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D018755:GABA Agonists / Q000008:administration & dosage*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage*; D000077334:Zolpidem
D015259:Dopamine Agents; D018755:GABA Agonists; D011725:Pyridines; D007980:Levodopa; D000077334:Zolpidem